BR100 Increased By (0.86%)
BR30 Increased By (0.94%)
KSE100 Increased By (0.81%)
KSE30 Increased By (0.88%)
AGHA 6.45 Increased By ▲ 0.07 (1.1%)
BECO 4.39 Increased By ▲ 0.04 (0.92%)
BML 62.50 Decreased By ▼ -0.05 (-0.08%)
BOP 31.51 Increased By ▲ 0.12 (0.38%)
CNERGY 11.80 Increased By ▲ 0.07 (0.6%)
CSIL 5.85 Decreased By ▼ -0.06 (-1.02%)
FCCL 61.80 Increased By ▲ 0.09 (0.15%)
FFL 15.04 Increased By ▲ 0.25 (1.69%)
FNEL 1.30 Increased By ▲ 0.06 (4.84%)
KEL 6.34 Increased By ▲ 0.02 (0.32%)
KOSM 5.80 Decreased By ▼ -0.10 (-1.69%)
LOTCHEM 24.89 Increased By ▲ 0.20 (0.81%)
MLCF 105.75 Increased By ▲ 1.82 (1.75%)
NBP 174.62 Increased By ▲ 1.30 (0.75%)
NCPL 52.11 Increased By ▲ 0.28 (0.54%)
NPL 54.61 Increased By ▲ 0.58 (1.07%)
OGDC 318.80 Increased By ▲ 2.93 (0.93%)
PACE 9.30 Increased By ▲ 0.04 (0.43%)
PAEL 35.80 Increased By ▲ 0.22 (0.62%)
PIBTL 14.22 Increased By ▲ 0.56 (4.1%)
PPL 229.00 Increased By ▲ 2.93 (1.3%)
PRL 81.70 Increased By ▲ 1.42 (1.77%)
PTC 47.00 Increased By ▲ 0.36 (0.77%)
SSGC 23.98 Increased By ▲ 0.16 (0.67%)
TBL 9.26 Increased By ▲ 0.02 (0.22%)
TELE 7.67 Increased By ▲ 0.12 (1.59%)
TPL 24.85 Increased By ▲ 0.31 (1.26%)
TPLP 12.91 Decreased By ▼ -0.08 (-0.62%)
TREET 26.00 Increased By ▲ 0.02 (0.08%)
TRG 53.74 Increased By ▲ 0.41 (0.77%)
By

PARIS: Late-stage data on an experimental COVID-19 vaccine from Sanofi and GSK has showed the shot confers protection against the Omicron variant of the vaccine, the French drugmaker said on Friday.

The vaccine targets the beta variant - first identified in South Africa - as well as the original Wuhan strain of the virus.

In a trial involving 13,000 adults, when given as a first dose the vaccine demonstrated an efficacy rate of 64.7% in people with symptomatic COVID, and 72% efficacy against infections specifically caused by the Omicron variant.

“Sanofi-GSK’s vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation,” Sanofi said in a statement.

Sanofi’s Paris-listed shares were up about 1.4% in morning trading.

Sanofi, Akhuwat Foundation bring diabetes education to schools

The new data supporting the vaccine will be submitted to regulatory authorities with the hope of making the shot available later this year, the companies said on Friday.

Comments

Comments are closed for this article.